RxDoctor Payments Data

James Call

Nurse Practitioner · Tupelo, MSNPI 1033759774

Payments from drug & device makers

$3,870in general payments, 2019–2025

Across 131 payments — averaging $29.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$998
  • Sumitomo Pharma America, Inc.$622
  • Dendreon Pharmaceuticals LLC$330
  • Johnson & Johnson$205
  • Boston Scientific$194
  • Bayer$177
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$56415%
  • Food & beverage$3,28785%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,870 in reported general payments places this provider in the 90th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$314,426
Medicare patients
912
Services billed
9,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron83$48,926
GemtesaVibegron59$34,796
Tamsulosin Hcl358$3,283
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam11$1,993
Trospium Chloride45$1,960
Estradiol12$1,104
Doxycycline Hyclate49$1,098
Alfuzosin Hcl ErAlfuzosin Hcl99$951
Finasteride77$936
Methenamine Hippurate13$931
NitrofurantoinNitrofurantoin Macrocrystal15$467
Levofloxacin24$338
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim83$332
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$309
Fluconazole42$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$78$48,92683 claims
Sumitomo Pharma America, Inc.Gemtesa$622$34,79659 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →